echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Long-acting growth hormone Somatrogon Treats Growth Hormone Deficiency In Children, Japan Phase 3 Clinical Success

    Long-acting growth hormone Somatrogon Treats Growth Hormone Deficiency In Children, Japan Phase 3 Clinical Success

    • Last Update: 2020-06-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    OPKO Health announced that its weekly somatrogon treatment of pediatric growth hormone deficiency (pGHD) has met its main and secondary goals in Phase 3 clinical trials in Japan, and has demonstrated that the efficacy and safety of once-a-week somatrogon is comparable to that of the once-a-day GENOTROPIN (growth hormone)Somatrogon is a new molecular entity that contains a natural sequence of human growth hormone and C-end polypeptide (CTP) in the human fluff membrane hCG beta chainCTP prolongs the half-life of growth hormoneSomatrogon has been named "Orphan Medicine" in the United States and the European Union for the treatment ofchildrenand adults with growth hormone deficiencyPhillip Frost, OPKO's Chairman and CEO, said: "We are pleased to announce that Somatrogon's Phase 3 clinical studies in Japan have yielded impressive top resultsThe results of Japan and key global Phase 3 pediatric trials have shown that the weekly somatrogon represents a significant advance in the field of pGHD and is likely to enhance patient compliance and quality of life"The data from Phase 3 clinical trials in Japan are encouraging and confirm the potential of providing weekly treatment options for childrenpGHD," said Brenda Cooperstone, chief development officer for rare diseases at Pfizer's global product development division atWe are committed to further promoting the treatment of patients with rare growth hormone diseases to reduce the burden on sick children and their families2014, Pfizer signed a global agreement with OPKO to develop and commercialize the treatment of GHDUnder the agreement, OPKO is responsible for implementing clinical programs and Pfizer is responsible for registering and commercializing the productThe two companies will assess, as appropriate, the possibility of other child and adult indications
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.